Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tofimilast · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Tofimilast | DRUG | - |
Inclusion Criteria: * Mild to moderate persistent asthma (NAEPP/GINA Step 2-3) * Reversibility to albuterol at least 12% and 200 mL Exclusion Criteria: * Any significant co-morbid disease, particularly cardiovascular * Use of any maintenance therapy except short acting bronchodilators * Smoking h...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Tofimilast is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for respiratory conditions. It has been studied in adults with asthma and chronic obstructive pulmonary disease (COPD). It is a Phase 2 drug and has not been approved by the FDA.
Tofimilast has been studied for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Clinical trials enrolled adults aged 18 and older with asthma and adults aged 40 and older with COPD. It remains an investigational therapy and is not approved for any indication.
Tofimilast is a phosphodiesterase 4 (PDE4) inhibitor. It targets the PDE4 enzyme subtypes PDE4A, PDE4B, PDE4C, and PDE4D. Inhibiting these enzymes is the intended mechanism of action for this small molecule in respiratory disease.
Tofimilast is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 2 clinical trials of the drug in asthma and chronic obstructive pulmonary disease.
Tofimilast is in Phase 2 development. It is an investigational drug and is not FDA approved. Both of its recorded Phase 2 trials have been completed, and no trials are currently active.
Tofimilast has been evaluated in two completed Phase 2 trials. NCT00219622 studied it in 300 adults with chronic obstructive pulmonary disease across the United States, Argentina, Brazil, Chile, Costa Rica, and Mexico. NCT00150397 studied it in 112 adult asthmatics in the United States, Costa Rica, and India.